Literature DB >> 2943825

Ligand-receptor interactions in the phagocytosis of virulent Streptococcus pneumoniae by polymorphonuclear leukocytes.

D L Gordon, G M Johnson, M K Hostetter.   

Abstract

We used polyclonal and monoclonal antibodies to neutrophil complement receptors CR1 and CR3 to assess the role of these receptors in the phagocytosis of virulent Streptococcus pneumoniae serotypes 3, 6A, and 14, which bear accessible C3 ligands covalently bound to the polysaccharide capsule. When the iC3b receptor (CR3) on normal polymorphonuclear leukocytes (PMNLs) was blocked by the monoclonal antibody OKM10, phagocytosis of pneumococcal serotypes 6A and 14 (which bear exclusively iC3b) was inhibited 50%-80% in pooled human serum and completely in nonimmune serum. Blockade of the PMNL C3b receptor (CR1) failed to inhibit phagocytosis for serotypes 6A and 14. For serotype 3, which bears C3b and C3d (as well as iC3b) on the capsule, CR3-mediated phagocytosis accounted for only 20% of the uptake; again, there was no evidence for CR1-mediated phagocytosis. The iC3b ligand elicited consistently greater release of superoxide, myeloperoxidase, and lactoferrin than did C3b. The iC3b/CR3 interaction is thus the primary trigger for phagocytosis of iC3b-bearing pneumococci and for stimulation of intracellular bactericidal processes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943825     DOI: 10.1093/infdis/154.4.619

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance.

Authors:  M J Blaser; P F Smith; J E Repine; K A Joiner
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

Review 2.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

Review 4.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

5.  Specificity of bovine serum antibody to capsular carbohydrate antigens from Pasteurella haemolytica.

Authors:  D S McVey; R W Loan; C W Purdy; W J Shuman
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.

Authors:  M K Hostetter; G M Johnson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 7.  CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.

Authors:  G D Ross; V Vĕtvicka
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

8.  Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides.

Authors:  C M Bendel; M K Hostetter
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

10.  Stress-induced differences in primary and secondary resistance against bacterial sepsis corresponds with diverse corticotropin releasing hormone receptor expression by pulmonary CD11c+ MHC II+ and CD11c- MHC II+ APCs.

Authors:  Xavier F Gonzales; Aniket Deshmukh; Mark Pulse; Khaisha Johnson; Harlan P Jones
Journal:  Brain Behav Immun       Date:  2007-12-31       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.